#NEWS: We’re excited to share that our Phase II trial in adults with metabolic dysfunction-associated steatohepatitis (MASH) & liver fibrosis stages F1, F2 & F3 met its primary endpoint & all key secondary endpoints.#LifeForward Learn more 👉 bit.ly/3Ibj5e8

#NEWS: We are expanding our mental health pipeline by partnering with @soseiheptaresco in an effort to further develop novel, first-in-class treatments for schizophrenia. Learn more: bit.ly/3PhlUhM #Schizophrenia #MentalHealth #ResearchAndDevelopment

#NEWS: U.S. FDA and the Chinese National Medical Products Administration (NMPA) approved our generalized pustular psoriasis (#GPP) treatment option for expanded indications. GPP is a chronic inflammatory disease, greatly impacting quality of life. ➡️ bit.ly/3ToXCnb

#Journalists: At our Annual #Press Conference on April 16, we'll discuss our performance and major milestones achieved in 2023 and provide an outlook for 2024 and beyond. Register now ➡️ bit.ly/3vrA8G9

#PRESS: In 2023 👉 we invested EUR 5.8 bn in #innovation 👉 helped more than 61 mln patients Our ≈ 53,500 employees keep working on breakthrough solutions that improve lives of humans & animals in a sustainable way. But there’s more! Check it out ➡️ bit.ly/4aOFDNW

#NEWS: Announcing our new partnership with Ochre Bio to develop novel regenerative treatments for patients with advanced liver disease, including metabolic associated steatohepatitis (#MASH) cirrhosis. Learn more: bit.ly/4d5DYpk #LiverDisease #ResearchAndDevelopment

#NEWS: We're excited to share our positive data from the Phase I/IIa HORNBILL study in diabetic macular ischema (DMI). #RetinalHealth #ARVO2024 Learn more 👉 bit.ly/3JUk5nD

#NEWS: We are excited to expand our partnership with OSE Immunotherapeutics - Biotechs & immunothérapie to develop novel first-in-class treatments for cancer and cardio-renal-metabolic (CRM) diseases. Learn more: bit.ly/3V9fWmn #CardioMetabolic #Cancer #ResearchAndDevelopment

#NEWS There is an imperative need to address the barriers around perception and gaps in care for mental health conditions, such as schizophrenia. Find out more in this new report from Economist Impact on how to ensure better care for every mind:

#NEWS: We look forward to working with AUROBAC THERAPEUTICS to develop a first-in-class septic shock treatment. AUROBAC is growing its pipeline focused on severe infections in acute hospital settings. Learn more: bit.ly/3yL3PDt #AMR #ResearchCollaboration

#NEWS: Our Ph II full data results for adults with #MASH and liver fibrosis F1, F2, & F3 showed the trial met all key secondary endpoints and its primary endpoint. The data were presented today at EASLnews. #LifeForward #EASLCongress Read more: bit.ly/3XaAtZ4

#NEWS: We are starting Phase 1 of a new first-in-class obesity treatment. BI 3034701 is a triple agonist developed with our partner Gubra to potentially transform patients' lives. Learn more: bit.ly/4blrbNu #CardioMetabolic #ResearchCollaboration #Innovation

#NEWS: We're taking a big step forward in our mission to transform cancer care. Our first-in-class SIRPα immuno-oncology program, initiated by OSE Immunotherapeutics - Biotechs & immunothérapie, is moving to the next clinical stage. Learn more: bit.ly/4cHPzd8 #Cancer #ImmunoOncology #ResearchAndDevelopment

#NEWS: With our new biomass power plant in Ingelheim we're producing more #sustainable energy for our site 💚 The inauguration took place today with the German Vice Chancellor Robert #Habeck Bundesministerium für Wirtschaft und Klimaschutz. 👉 bit.ly/3zrMek4

#NEWS: So far in 2024, our pipeline has advanced significantly across our key therapy areas. We’ve increased our R&D investment, accelerating our launch readiness. Read more about our key performance figures as well as an outlook on our innovation efforts: bit.ly/3W5aGzv

#NEWS: The European Committee for Medicinal Products for Human Use (CHMP) recommends approval of new and expanded indications for our generalized pustular psoriasis (#GPP) treatment option: bit.ly/3WogEvg

#NEWS: We have acquired Nerio Therapeutics. Why? Their knowledge will help us to fight cancer by activating our own immune system. Learn more on why we have added their small molecule checkpoint inhibitor to our oncology pipeline: bit.ly/NerioTherapeut…

We’ve discovered a way to potentially treat #KRAS-driven #cancer more effectively and delay the onset of drug resistance using a drug combination. This research published in Nature Cancer was done in collaboration with MD Anderson Cancer Center. Learn more here: go.nature.com/3LVzi9i

#NEWS: Transformative results for our investigational medicine will be shared at the 2024 World Conference on Lung Cancer, for patients with HER2-mutated Non-Small Cell Lung Cancer and who have received prior systemic therapy.  Learn more: bitly.cx/Ni1b5

#NEWS: Following Phase I results, we're planning to advance a potential new treatment of Geographic Atrophy. We developed the antibody BI 771716 using technology licensed from CDR-Life   Learn more 👉 bit.ly/3zadtQv   #RetinalDiseases #ClinicalTrials #VisionHealth